Skip To Content

Bioventus Securities Litigation

877-933-2890

This official website is maintained by the Claims Administrator under the supervision of Lead Counsel for the members of the Settlement Class in Ciarciello v. Bioventus, Inc., et al., Case No. 1:23-cv-00032-CCE-JEP (M.D.N.C.) which is pending in the United States District Court For the Middle District of North Carolina.

Bioventus Securities Litigation

ALL PERSONS AND ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED BIOVENTUS CLASS A COMMON STOCK BETWEEN FEBRUARY 11, 2021, AND NOVEMBER 21, 2022, BOTH INCLUSIVE.
The information contained on this web page is only a summary of the detailed information presented in the Long-Form Notice of Pendency and Proposed Settlement of Class Action (the “Notice”), which you can access by clicking here. Since this website is just a summary, you should review the Notice for additional information.

If you are a Settlement Class Member, your legal rights will be affected by this Settlement whether you act or do not act.

Please read the Notice carefully.

ALL PERSONS AND ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED BIOVENTUS CLASS A COMMON STOCK BETWEEN FEBRUARY 11, 2021, AND NOVEMBER 21, 2022, BOTH INCLUSIVE.

Your Legal Rights and Options In The Settlement
Description Due Date

Submit a Claim

This is the only way to be eligible to receive a payment. If you are a Settlement Class Member, and do not exclude yourself from the Settlement Class, you will be bound by the Settlement as approved by the Court and you will give up any “Released Claims” that you have against the Defendants and their “Related Parties”. 

The deadline to file a claim passed on December 2, 2024.

Exclude Yourself

If you exclude yourself from the Settlement Class, you will not be eligible to receive any payment from the Settlement Fund. This is the only option that potentially allows you to participate in another lawsuit against the Defendants or their Related Parties relating to the Released Claims being released in this case. Should you elect to exclude yourself from the Settlement Class, you should understand that Defendants and their Related Parties will have the right to assert any and all defenses they may have to any claims that you may seek to assert, including, without limitation, the defense that any such claims are untimely under applicable statutes of limitations and statutes of repose.

The deadline to exclude yourself from the Settlement passed on October 18, 2024.

Object

You may write to the Court if you do not like this Settlement, the Plan of Allocation and/or the request for attorneys’ fees and expenses. You will still be a Member of the Settlement Class.

The deadline to object to the Settlement passed on November 22, 2024.

Go to a Hearing on December 13, 2024, at 9:30 A.M.

On December 18, 2024, the Court granted final approval of the Settlement, Plan of Allocation, and Plaintiff's motion for attorney fees and costs. Please find the relevant Order in the Court Documents section of this website. 

Do Nothing

If you are a Member of the Settlement Class and you do not submit a Proof of Claim by December 2, 2024, you will not be eligible to receive any payment from the Net Settlement Fund. You will, however, remain a Member of the Settlement Class, which means that you give up your right to sue about the claims that are resolved by the Settlement and you will still be bound by any judgments or orders entered by the Court in the Litigation.

How do I know if I am part of the Settlement Class?

For the purposes of settlement, everyone who fits the following description is a Settlement Class Member. Please read Question Number 7 in the Notice for exceptions to inclusion in the Settlement Class.

The Settlement Class includes all persons and entities who purchased or otherwise acquired Bioventus Class A common stock between February 11, 2021, and November 21, 2022, both inclusive (the “Class Period”), and were damaged thereby.

How much will my payment be?

Your payment (if any) will depend on several things, including the total dollar amount of claims represented by the valid Proofs of Claim that Settlement Class Members submit; the number of shares of Bioventus Class A common stock you purchased or acquired; how much you paid for those shares; when you purchased or acquired them; and if and when you sold your shares of Bioventus Class A common stock and for how much. The Claims Administrator will apply the Plan of Allocation to calculate the amount of your Recognized Claim, and your payment (if any) will be a portion of the Net Settlement Fund equal to your Recognized Claim divided by the total of all Authorized Claimants’ Recognized Claims.

The Settlement Hearing

On December 18, 2024, the Court granted final approval of the Settlement, Plan of Allocation, and Plaintiff's motion for attorney fees and costs. Please find the relevant Order in the Court Documents section of this website. 

Further Information

For more details regarding this case, please reference the documents filed in the case under the “Court Documents” section at the top of this website. You may also contact the Claims Administrator or Lead Counsel for further information regarding this case.

Claims Administrator:
Bioventus Securities Litigation
Claims Administrator
c/o A.B. Data, Ltd.
P.O. Box 173114
Milwaukee, WI 53217
Email: info@bioventussecuritieslitigation.com
Telephone: (877) 933-2890

Lead Counsel:
Joseph A. Fonti
Bleichmar Fonti & Auld LLP
300 Park Ave, Suite 1301
New York, NY 10022
Email: bioventussettlement@bfalaw.com
Telephone: (888) 879-9418